Join
Live feed
·
PRReleasevia Quantisnow
Absci Corporation logo

Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)

ByQuantisnow·Wall Street's wire, on your screen.
ABSI· Absci Corporation
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ABSI (Absci Corporation) and more on Quantisnow.